Table 5.

Treatment-related adverse events^a.

	Dacarbazine-based (n = 17)		Temozolomide-based (n = 10)		P-value		Total (n = 27)
	All grades, n/N	Grades 3–4, n/N	All grades, n/N	Grades 3–4, n/N	All grades	Grades 3–4	All grades, n/N	Grades 3–4, n/N
Fatigue	12/14	1/14	9/10	1/10	0.36	0.83	21/24	2/24
Nausea/vomiting	7/13	0/13	2/9	1/9	0.15	0.05	9/22	1/22
Diarrhoea	7/15	1/15	2/9	0/9	0.58	0.57	9/24	1/24
Mucositis	1/13	1/13	2/9	0/9	0.16	0.08	3/22	1/22
Palmar-plantar erythrodysesthesia syndrome	1/13	0/13	4/9	1/9	0.12	0.58	5/22	1/22
Anaemia	10/14	0/14	8/9	1/9	0.49	0.25	18/23	1/23
Neutropenia	1/14	1/14	5/9	1/9	0.04	0.12	6/23	2/23
Febrile neutropenia	0/14	0/14	0/9	0/9	-	-	0/23	0/23
Thrombocytopenia	4/14	1/14	8/9	1/9	0.03	0.58	12/23	2/23
Otherb	4/15	0/15	2/9	0/9	0.73	-	6/24	0/24

N, number of patients with available data for this variable.

^aAdverse events were graded according to the Common Terminology Criteria for Adverse Event version 4.03 (CTCAE v4.03). ^bOther: constipation (n = 3), abdominal pain (n = 1), acute renal failure (n = 1), and dysesthesia (n = 1).